|Day Low/High||37.60 / 38.08|
|52 Wk Low/High||36.00 / 46.22|
Horizon Pharma is a 'giant headache,' says Jim Cramer; Abbot Labs is OK long term.
Holiday-shortened week holds a feast of earnings reports, says Jim Cramer.
European Union regulators are expected to approve Abbott Laboratories' $33 billion acquisition of St. Jude Medical.
- Japan approval makes first-of-its-kind medical device available to people in Japan with coronary artery disease who prefer an alternative to a permanent metallic implant
Abbott wants more information from Alere, as promised under their pending $7.9 billion agreement.
TOP SCIENTIST: ABBOTT'S INNOVATION MISSION APPEALS TO 'HEARTS AND MINDS' OF SCIENTISTS
Levels of FIVE immune markers were nearly identical in breastfed babies and babies fed formula with 2'-FL Human milk oligosaccharide
The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.
Look for ABT's declining trend to continue a while longer.
Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.
St. Jude shares deserve to be higher ahead of the merger with Abbott Labs. Here's why.
Shares of the medical-device giant were climbing after unveiling strong earnings.
Political pressure is weighing on drug and medical device stocks including Abbott Labs and St. Jude, says Jim Cramer.
Miles White also reiterated that Abbott Laboratories has no plans to divest of its diabetes business. He still believes in Alere over the long term.
The medical device maker responded to allegations that its devices could be hacked during its third quarter earnings call.
Abbott Labs ABT) on Wednesday morning posted earnings that were above analysts' expectations for the 2016 third quarter.
U.S. stock futures turn mixed; Yahoo!'s adjusted earnings top forecasts but revenue falls 14% in the third quarter; Intel guides to fourth-quarter revenue below consensus.
They plan to sell portions of their vascular closure and electrophysiology businesses to Japan's Terumo Corp. for $1.12 billion.
- The agreement is an important step toward completion of Abbott's acquisition of St. Jude Medical
On Wednesday, Abbott (ABT) is expected to post third-quarter earnings and revenue that are higher than a year ago.
Some of our favorite stocks will report earnings this week; here's a look at what else Jim Cramer is keeping an eye on.
Political anxiety, weak earnings and the dread of rising interest rates are weighing on markets. Here's how to protect your portfolio.
Cramer says his game plan is all about earnings, when the fundamentals control the market.
Illumina fell 24% on news that it was cutting revenue guidance.